- Home
- ANTX vs AKTX Comparison
ANTX vs AKTX Comparison
Compare ANTX & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANTX
- AKTX
- Stock Information
- Founded
- ANTX 2017
- AKTX N/A
- Country
- ANTX United States
- AKTX United States
- Employees
- ANTX N/A
- AKTX N/A
- Industry
- ANTX Biotechnology: Pharmaceutical Preparations
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- ANTX Health Care
- AKTX Health Care
- Exchange
- ANTX Nasdaq
- AKTX Nasdaq
- Market Cap
- ANTX 31.4M
- AKTX 35.7M
- IPO Year
- ANTX 2022
- AKTX N/A
- Fundamental
- Price
- ANTX $1.26
- AKTX $0.73
- Analyst Decision
- ANTX Buy
- AKTX Strong Buy
- Analyst Count
- ANTX 2
- AKTX 1
- Target Price
- ANTX $2.00
- AKTX $5.00
- AVG Volume (30 Days)
- ANTX 84.9K
- AKTX 82.8K
- Earning Date
- ANTX 08-12-2025
- AKTX 08-13-2025
- Dividend Yield
- ANTX N/A
- AKTX N/A
- EPS Growth
- ANTX N/A
- AKTX N/A
- EPS
- ANTX N/A
- AKTX N/A
- Revenue
- ANTX N/A
- AKTX N/A
- Revenue This Year
- ANTX N/A
- AKTX N/A
- Revenue Next Year
- ANTX N/A
- AKTX N/A
- P/E Ratio
- ANTX N/A
- AKTX N/A
- Revenue Growth
- ANTX N/A
- AKTX N/A
- 52 Week Low
- ANTX $0.98
- AKTX $0.57
- 52 Week High
- ANTX $1.68
- AKTX $3.87
- Technical
- Relative Strength Index (RSI)
- ANTX 67.16
- AKTX 29.44
- Support Level
- ANTX $1.09
- AKTX $0.57
- Resistance Level
- ANTX $1.29
- AKTX $1.01
- Average True Range (ATR)
- ANTX 0.06
- AKTX 0.07
- MACD
- ANTX 0.02
- AKTX -0.02
- Stochastic Oscillator
- ANTX 87.50
- AKTX 33.19
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.